Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...
Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...
The company said Monday that fosigotifator failed to outperform placebo in slowing the neurodegenerative disease, but is ...
A study of human brain organoids suggested a complex relationship between herpes simplex virus 1 infection and tau, ...
Most recently, Denali Therapeutics initiated dosing in a global BEACON Phase 2a trial of BIIB122 (DNL151) for LRRK2-associated Parkinson’s disease. Denali’s market cap stands at $2.93 billion ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Denali Therapeutics Inc. has a 12 month low of $14.56 and a 12 month high of $33.33. Get Denali Therapeutics alerts: Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last released its ...
Shares of DNLI stock opened at $21.26 on Friday. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $33.33. The firm has a fifty day moving average of $24.62 and a 200-day ...
William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for neurodegenerative diseases. The analyst highlights that Denali is developing a ...